Share

Locarnini, Stephen au

List of all publications

Publishing since 1993 (Senior)

    2010

  1. Journal ArticleResearch Support, N.I.H., Extramural Crane M, Sirivichayakul S, Chang JJ, Avihingsanon A, Ubolyam S, Buranapraditkun S, Thantiworasit P, Wightman F, Locarnini S, Matthews G, Dore GJ, Ruxrungtham K, Lewin SR. No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy.  J. Virol.  2010;84;6  Link to No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy.
  2. Journal Article Revill P, Yuen L, Walsh R, Perrault M, Locarnini S, Kramvis A. Bioinformatic analysis of the hepadnavirus e-antigen and its precursor identifies remarkable sequence conservation in all orthohepadnaviruses.  J. Med. Virol.  2010;82;1  Link to Bioinformatic analysis of the hepadnavirus e-antigen and its precursor identifies remarkable sequence conservation in all orthohepadnaviruses.

    3. 2009

  3. Journal ArticleResearch Support, N.I.H., ExtramuralReview Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues.  Gastroenterology  2009;137;5  Link to Hepatitis B virus resistance to nucleos(t)ide analogues.
  4. Journal Article Nguyen T, Locarnini S. Hepatitis: Monitoring drug therapy for hepatitis B--a global challenge?  Nat Rev Gastroenterol Hepatol  2009;6;10  Link to Hepatitis: Monitoring drug therapy for hepatitis B--a global challenge?
  5. Journal Article Nguyen T, Desmond P, Locarnini S. The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B.  Hepatology international  2009  Link to The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B.
  6. Clinical TrialJournal ArticleMulticenter StudyResearch Support, N.I.H., Extramural Matthews GV, Seaberg E, Dore GJ, Bowden S, Lewin SR, Sasadeusz J, Marks P, Goodman Z, Philp FH, Tang Y, Locarnini S, Thio CL. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals.  AIDS  2009;23;13  Link to Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals.
  7. Journal ArticleResearch Support, N.I.H., Extramural Chang JJ, Sirivichayakul S, Avihingsanon A, Thompson AJ, Revill P, Iser D, Slavin J, Buranapraditkun S, Marks P, Matthews G, Cooper DA, Kent SJ, Cameron PU, Sasadeusz J, Desmond P, Locarnini S, Dore GJ, Ruxrungtham K, Lewin SR. Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection.  J. Virol.  2009;83;15  Link to Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection.
  8. Evaluation StudiesJournal Article Kamili S, Sozzi V, Thompson G, Campbell K, Walker CM, Locarnini S, Krawczynski K. Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model.  Hepatology  2009;49;5  Link to Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model.
  9. Journal Article Thompson AJ, Colledge D, Rodgers S, Wilson R, Revill P, Desmond P, Mansell A, Visvanathan K, Locarnini S. Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro.  Antivir. Ther. (Lond.)  2009;14;6  Link to Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro.
  10. Journal Article Warner N, Locarnini S. Can antiviral therapy for chronic hepatitis B enhance the progression to hepatocellular carcinoma?  Antivir. Ther. (Lond.)  2009;14;2  Link to Can antiviral therapy for chronic hepatitis B enhance the progression to hepatocellular carcinoma?

    11. 2008

  11. Journal ArticleResearch Support, N.I.H., Extramural Preiss S, Thompson A, Chen X, Rodgers S, Markovska V, Desmond P, Visvanathan K, Li K, Locarnini S, Revill P. Characterization of the innate immune signalling pathways in hepatocyte cell lines.  J. Viral Hepat.  2008;15;12  Link to Characterization of the innate immune signalling pathways in hepatocyte cell lines.
  12. Congresses Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR, Zoulim F. Statements from the Taormina expert meeting on occult hepatitis B virus infection.  J. Hepatol.  2008;49;4  Link to Statements from the Taormina expert meeting on occult hepatitis B virus infection.
  13. Journal ArticleRandomized Controlled Trial Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, Petcharapirat P, Marks P, Sasadeusz J, Cooper DA, Bowden S, Locarnini S, Ruxrungtham K, Dore GJ. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.  Hepatology  2008;48;4  Link to A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
  14. Journal Article Poustchi H, Mohamadkhani A, Bowden S, Montazeri G, Ayres A, Revill P, Farrell GC, Locarnini S, George J, Malekzadeh R. Clinical significance of precore and core promoter mutations in genotype D hepatitis B-related chronic liver disease.  J. Viral Hepat.  2008;15;10  Link to Clinical significance of precore and core promoter mutations in genotype D hepatitis B-related chronic liver disease.
  15. Journal ArticleResearch Support, N.I.H., Extramural Preiss S, Littlejohn M, Angus P, Thompson A, Desmond P, Lewin SR, Sasadeusz J, Matthews G, Dore GJ, Shaw T, Sozzi V, Yuen L, Lau G, Ayres A, Thio C, Avihingsanon A, Ruxrungtham K, Locarnini S, Revill PA. Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance.  Hepatology  2008;48;3  Link to Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance.
  16. Journal Article Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.  Hepatology international  2008;2;3  Link to Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.
  17. CommentEditorial Nguyen T, Locarnini S, Desmond P. Changing landscape of antiviral resistance management in chronic hepatitis B.  J. Gastroenterol. Hepatol.  2008;23;9  Link to Changing landscape of antiviral resistance management in chronic hepatitis B.
  18. Journal ArticleResearch Support, N.I.H., Extramural Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound.  Hepatology  2008;48;1  Link to The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound.
  19. Journal Article Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure.  Hepatology international  2008;2;2  Link to Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure.
  20. Journal Article Locarnini S. Introduction.  Hepatology international  2008;2;Supplement 1  Link to Introduction.
  21. Journal ArticleRandomized Controlled Trial Hui CK, Zhang HY, Bowden S, Locarnini S, Luk JM, Leung KW, Yueng YH, Wong A, Rousseau F, Yuen KY, Naoumov NN, Lau GK. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B.  J. Hepatol.  2008;48;5  Link to 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B.
  22. Comparative StudyJournal Article Sung JJ, Tsui SK, Tse CH, Ng EY, Leung KS, Lee KH, Mok TS, Bartholomeusz A, Au TC, Tsoi KK, Locarnini S, Chan HL. Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virus.  J. Virol.  2008;82;7  Link to Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virus.
  23. Journal ArticleResearch Support, N.I.H., ExtramuralResearch Support, N.I.H., IntramuralReview Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, Locarnini S, Martin P, Richman DD, Zoulim F. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.  Gastroenterology  2008;134;2  Link to Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.

    24. 2007

  24. Journal Article Sheldon J, Ramos B, Garcia-Samaniego J, Rios P, Bartholomeusz A, Romero M, Locarnini S, Zoulim F, Soriano V. Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity.  J. Acquir. Immune Defic. Syndr.  2007;46;3  Link to Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity.
  25. Journal ArticleReview Gish RG, Locarnini S. Genotyping and genomic sequencing in clinical practice.  Clin Liver Dis  2007;11;4  Link to Genotyping and genomic sequencing in clinical practice.
  26. CommentEditorial Thompson A, Locarnini S, Visvanathan K. The natural history and the staging of chronic hepatitis B: time for reevaluation of the virus-host relationship based on molecular virology and immunopathogenesis considerations?  Gastroenterology  2007;133;3  Link to The natural history and the staging of chronic hepatitis B: time for reevaluation of the virus-host relationship based on molecular virology and immunopathogenesis considerations?
  27. Journal ArticleResearch Support, N.I.H., ExtramuralReview Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.  Hepatology  2007;46;1  Link to Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.
  28. Journal ArticleReview Locarnini S, Warner N. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.  Antivir. Ther. (Lond.)  2007;12 Suppl 3  Link to Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.
  29. Journal ArticleResearch Support, N.I.H., ExtramuralReview Thio CL, Locarnini S. Treatment of HIV/HBV coinfection: clinical and virologic issues.  AIDS Rev  2007;9;1  Link to Treatment of HIV/HBV coinfection: clinical and virologic issues.
  30. Journal Article Visvanathan K, Skinner NA, Thompson AJ, Riordan SM, Sozzi V, Edwards R, Rodgers S, Kurtovic J, Chang J, Lewin S, Desmond P, Locarnini S. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein.  Hepatology  2007;45;1  Link to Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein.

    31. 2006

  31. Comparative StudyJournal Article Riordan SM, Skinner N, Kurtovic J, Locarnini S, Visvanathan K. Reduced expression of toll-like receptor 2 on peripheral monocytes in patients with chronic hepatitis B.  Clin. Vaccine Immunol.  2006;13;8  Link to Reduced expression of toll-like receptor 2 on peripheral monocytes in patients with chronic hepatitis B.
  32. Journal Article Riordan SM, Skinner NA, Kurtovic J, Locarnini S, McIver CJ, Williams R, Visvanathan K. Toll-like receptor expression in chronic hepatitis C: correlation with pro-inflammatory cytokine levels and liver injury.  Inflamm. Res.  2006;55;7  Link to Toll-like receptor expression in chronic hepatitis C: correlation with pro-inflammatory cytokine levels and liver injury.
  33. Journal ArticleMulticenter StudyResearch Support, N.I.H., Extramural Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, Cooper DA, Lewin S, Dore GJ, Thio CL. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.  AIDS  2006;20;6  Link to Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.
  34. Journal ArticleReview Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation.  J. Hepatol.  2006;44;3  Link to HBV drug resistance: mechanisms, detection and interpretation.
  35. Journal ArticleResearch Support, N.I.H., ExtramuralReview Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance.  J. Hepatol.  2006;44;2  Link to Cellular and virological mechanisms of HBV drug resistance.
  36. Journal ArticleMulticenter StudyRandomized Controlled Trial Lim SG, Wai CT, Lee YM, Dan YY, Sutedja DS, Wee A, Suresh S, Wu YJ, Machin D, Lim CC, Fock KM, Koay E, Bowden S, Locarnini S, Ishaque SM. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B.  Antivir. Ther. (Lond.)  2006;11;2  Link to A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B.
  37. Journal Article Bartholomeusz A, Locarnini S. Hepatitis B virus mutations associated with antiviral therapy.  J. Med. Virol.  2006;78 Suppl 1  Link to Hepatitis B virus mutations associated with antiviral therapy.

    38. 2005

  38. Journal ArticleReview Locarnini S. Hepatitis C and hepatitis E vaccines: research update.  Med. J. Malaysia  2005;60 Suppl B  Link to Hepatitis C and hepatitis E vaccines: research update.
  39. Journal ArticleReview Locarnini S. Interpretation and application of virological testing including resistance in chronic hepatitis B.  Med. J. Malaysia  2005;60 Suppl B  Link to Interpretation and application of virological testing including resistance in chronic hepatitis B.
  40. Journal Article Chan HL, Tsui SK, Tse CH, Ng EY, Au TC, Yuen L, Bartholomeusz A, Leung KS, Lee KH, Locarnini S, Sung JJ. Epidemiological and virological characteristics of 2 subgroups of hepatitis B virus genotype C.  J. Infect. Dis.  2005;191;12  Link to Epidemiological and virological characteristics of 2 subgroups of hepatitis B virus genotype C.
  41. Clinical TrialJournal ArticleRandomized Controlled Trial Sung JJ, Wong ML, Bowden S, Liew CT, Hui AY, Wong VW, Leung NW, Locarnini S, Chan HL. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy.  Gastroenterology  2005;128;7  Link to Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy.
  42. CommentEditorialReview Locarnini S. Therapies for hepatitis B: where to from here?  Gastroenterology  2005;128;3  Link to Therapies for hepatitis B: where to from here?
  43. Case ReportsJournal Article Hui CK, Yu J, Au WY, Zhang HY, Bartholomeusz A, Locarnini S, Kwong YL, Liang R, Lau GK. Sexual transmission of hepatitis B infection despite the presence of hepatitis B virus immunity in recipients of allogeneic bone marrow transplantation.  J. Clin. Virol.  2005;32;2  Link to Sexual transmission of hepatitis B infection despite the presence of hepatitis B virus immunity in recipients of allogeneic bone marrow transplantation.
  44. Journal Article Locarnini S, Shaw T, Dean J, Colledge D, Thompson A, Li K, Lemon SM, Lau GG, Beard MR. Cellular response to conditional expression of the hepatitis B virus precore and core proteins in cultured hepatoma (Huh-7) cells.  J. Clin. Virol.  2005;32;2  Link to Cellular response to conditional expression of the hepatitis B virus precore and core proteins in cultured hepatoma (Huh-7) cells.
  45. Clinical TrialJournal Article Sheldon J, Camino N, Rodés B, Bartholomeusz A, Kuiper M, Tacke F, Núñez M, Mauss S, Lutz T, Klausen G, Locarnini S, Soriano V. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.  Antivir. Ther. (Lond.)  2005;10;6  Link to Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.
  46. Journal ArticleReview Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy.  Semin. Liver Dis.  2005;25 Suppl 1  Link to Molecular virology and the development of resistant mutants: implications for therapy.

    47. 2004

  47. Journal ArticleReview Shaw T, Locarnini S. Entecavir for the treatment of chronic hepatitis B.  Expert Rev Anti Infect Ther  2004;2;6  Link to Entecavir for the treatment of chronic hepatitis B.
  48. Journal Article Norder H, Couroucé AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, Robertson BH, Locarnini S, Magnius LO. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes.  Intervirology  2004;47;6  Link to Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes.
  49. Journal Article Jazayeri M, Basuni AA, Sran N, Gish R, Cooksley G, Locarnini S, Carman WF. HBV core sequence: definition of genotype-specific variability and correlation with geographical origin.  J. Viral Hepat.  2004;11;6  Link to HBV core sequence: definition of genotype-specific variability and correlation with geographical origin.
  50. Journal ArticleReview Locarnini S, Hatzakis A, Heathcote J, Keeffe EB, Liang TJ, Mutimer D, Pawlotsky JM, Zoulim F. Management of antiviral resistance in patients with chronic hepatitis B.  Antivir. Ther. (Lond.)  2004;9;5  Link to Management of antiviral resistance in patients with chronic hepatitis B.
  51. Journal Article Basuni AA, Butterworth L, Cooksley G, Locarnini S, Carman WF. Prevalence of HBsAg mutants and impact of hepatitis B infant immunisation in four Pacific Island countries.  Vaccine  2004;22;21-22  Link to Prevalence of HBsAg mutants and impact of hepatitis B infant immunisation in four Pacific Island countries.
  52. Journal Article Jazayeri MS, Basuni AA, Cooksley G, Locarnini S, Carman WF. Hepatitis B virus genotypes, core gene variability and ethnicity in the Pacific region.  J. Hepatol.  2004;41;1  Link to Hepatitis B virus genotypes, core gene variability and ethnicity in the Pacific region.
  53. Journal Article Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WE, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.  Gastroenterology  2004;126;7  Link to Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.
  54. Journal ArticleReview Lee JY, Locarnini S. Hepatitis B virus: pathogenesis, viral intermediates, and viral replication.  Clin Liver Dis  2004;8;2  Link to Hepatitis B virus: pathogenesis, viral intermediates, and viral replication.
  55. CommentEditorial Angus P, Locarnini S. Lamivudine-resistant hepatitis B virus and ongoing lamivudine therapy: stop the merry-go-round, it's time to get off!  Antivir. Ther. (Lond.)  2004;9;2  Link to Lamivudine-resistant hepatitis B virus and ongoing lamivudine therapy: stop the merry-go-round, it's time to get off!
  56. Journal ArticleReview Locarnini S. Molecular virology of hepatitis B virus.  Semin. Liver Dis.  2004;24 Suppl 1  Link to Molecular virology of hepatitis B virus.
  57. CommentEditorialReview Shaw T, Bowden S, Locarnini S. Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy?  Gastroenterology  2004;126;1  Link to Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy?

    58. 2003

  58. Journal ArticleReview Feld J, Lee JY, Locarnini S. New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B.  Hepatology  2003;38;3  Link to New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B.
  59. Journal Article Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A, Locarnini S. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.  Gastroenterology  2003;125;2  Link to Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.
  60. Journal Article Schilling R, Ijaz S, Davidoff M, Lee JY, Locarnini S, Williams R, Naoumov NV. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions.  J. Virol.  2003;77;16  Link to Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions.
  61. Journal Article Cooley L, Ayres A, Bartholomeusz A, Lewin S, Crowe S, Mijch A, Locarnini S, Sasadeusz J. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals.  AIDS  2003;17;11  Link to Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals.
  62. Journal Article Klein C, Bock CT, Wedemeyer H, Wüstefeld T, Locarnini S, Dienes HP, Kubicka S, Manns MP, Trautwein C. Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA.  Gastroenterology  2003;125;1  Link to Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA.
  63. Journal ArticleReview Chin R, Locarnini S. Treatment of chronic hepatitis B: current challenges and future directions.  Rev. Med. Virol.  2003;13;4  Link to Treatment of chronic hepatitis B: current challenges and future directions.
  64. Case ReportsJournal Article Ayres A, Bartholomeusz A, Lau G, Lam KC, Lee JY, Locarnini S. Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure.  J. Clin. Virol.  2003;27;1  Link to Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure.
  65. EditorialReview Bowden S, Bartholomeusz A, Locarnini S. Lamivudine resistant occult HBV: implications for public health?  J. Hepatol.  2003;38;4  Link to Lamivudine resistant occult HBV: implications for public health?
  66. Journal ArticleReview Locarnini S, McMillan J, Bartholomeusz A. The hepatitis B virus and common mutants.  Semin. Liver Dis.  2003;23;1  Link to The hepatitis B virus and common mutants.
  67. Journal ArticleReview Locarnini S. Hepatitis B viral resistance: mechanisms and diagnosis.  J. Hepatol.  2003;39 Suppl 1  Link to Hepatitis B viral resistance: mechanisms and diagnosis.

    68. 2002

  68. CommentJournal ArticleReview Shaw T, Bowden S, Locarnini S. Chemotherapy for hepatitis B: new treatment options necessitate reappraisal of traditional endpoints.  Gastroenterology  2002;123;6  Link to Chemotherapy for hepatitis B: new treatment options necessitate reappraisal of traditional endpoints.
  69. Journal ArticleReview Feld J, Locarnini S. Antiviral therapy for hepatitis B virus infections: new targets and technical challenges.  J. Clin. Virol.  2002;25;3  Link to Antiviral therapy for hepatitis B virus infections: new targets and technical challenges.
  70. Journal ArticleReview Lewin S, Walters T, Locarnini S. Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies.  Antiviral Res.  2002;55;3  Link to Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies.
  71. Clinical TrialControlled Clinical TrialJournal Article Lau GK, He ML, Fong DY, Bartholomeusz A, Au WY, Lie AK, Locarnini S, Liang R. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.  Hepatology  2002;36;3  Link to Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.
  72. Journal Article Sievert W, Pianko S, Warner S, Bowden S, Simpson I, Bowden D, Locarnini S. Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major.  Am. J. Gastroenterol.  2002;97;4  Link to Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major.
  73. Journal Article Bock CT, Tillmann HL, Torresi J, Klempnauer J, Locarnini S, Manns MP, Trautwein C. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation.  Gastroenterology  2002;122;2  Link to Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation.
  74. Case ReportsCommentLetter Bonacini M, Kurz A, Locarnini S, Ayres A, Gibbs C. Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV.  Gastroenterology  2002;122;1  Link to Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV.

    75. 2001

  75. Comparative StudyJournal Article Colonno RJ, Genovesi EV, Medina I, Lamb L, Durham SK, Huang ML, Corey L, Littlejohn M, Locarnini S, Tennant BC, Rose B, Clark JM. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.  J. Infect. Dis.  2001;184;10  Link to Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.
  76. Journal ArticleResearch Support, U.S. Gov't, P.H.S. Lewin SR, Ribeiro RM, Walters T, Lau GK, Bowden S, Locarnini S, Perelson AS. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed.  Hepatology  2001;34;5  Link to Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed.
  77. CommentEditorialReview Bartholomeusz A, Locarnini S. Hepatitis B virus mutants and fulminant hepatitis B: fitness plus phenotype.  Hepatology  2001;34;2  Link to Hepatitis B virus mutants and fulminant hepatitis B: fitness plus phenotype.
  78. Journal Article Lee JY, Culvenor JG, Angus P, Smallwood R, Nicoll A, Locarnini S. Duck hepatitis B virus replication in primary bile duct epithelial cells.  J. Virol.  2001;75;16  Link to Duck hepatitis B virus replication in primary bile duct epithelial cells.

    79. 2000

  79. Journal ArticleReview Locarnini S. Molecular pathogenesis of viral hepatitis.  J. Gastroenterol. Hepatol.  2000;15 Suppl  Link to Molecular pathogenesis of viral hepatitis.
  80. Journal ArticleReview Shaw T, Locarnini S. Combination chemotherapy for hepatitis B virus: the path forward?  Drugs  2000;60;3  Link to Combination chemotherapy for hepatitis B virus: the path forward?
  81. CommentEditorial Shaw T, Locarnini S. Combination chemotherapy for hepatitis B virus: the final solution?  Hepatology  2000;32;2  Link to Combination chemotherapy for hepatitis B virus: the final solution?
  82. Journal Article Wilson N, Ruff TA, Rana BJ, Leydon J, Locarnini S. The effectiveness of the infant hepatitis B immunisation program in Fiji, Kiribati, Tonga and Vanuatu.  Vaccine  2000;18;26  Link to The effectiveness of the infant hepatitis B immunisation program in Fiji, Kiribati, Tonga and Vanuatu.
  83. Journal ArticleReview Locarnini S. A virological perspective on the need for vaccination.  J. Viral Hepat.  2000;7 Suppl 1  Link to A virological perspective on the need for vaccination.
  84. Comparative StudyJournal Article Basuni AA, Butterworth LA, Cooksley G, Locarnini S, Carman WF. An efficient extraction method from blood clots for studies requiring both host and viral DNA.  J. Viral Hepat.  2000;7;3  Link to An efficient extraction method from blood clots for studies requiring both host and viral DNA.
  85. Comparative StudyJournal Article Nicoll A, Locarnini S, Chou ST, Smallwood R, Angus P. Effect of nucleoside analogue therapy on duck hepatitis B viral replication in hepatocytes and bile duct epithelial cells in vivo.  J. Gastroenterol. Hepatol.  2000;15;3  Link to Effect of nucleoside analogue therapy on duck hepatitis B viral replication in hepatocytes and bile duct epithelial cells in vivo.
  86. Journal ArticleReview Torresi J, Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections.  Gastroenterology  2000;118;2 Suppl 1  Link to Antiviral chemotherapy for the treatment of hepatitis B virus infections.

    87. 1999

  87. CommentEditorial Bowden S, Locarnini S. TT virus: an agent of transfusion-associated hepatitis or yellow herring?  J. Gastroenterol. Hepatol.  1999;14;4  Link to TT virus: an agent of transfusion-associated hepatitis or yellow herring?
  88. Journal ArticleReview Locarnini S, Birch C. Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients.  J. Hepatol.  1999;30;3  Link to Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients.

    89. 1998

  89. Journal Article Chin R, Locarnini S. New therapies for the treatment of chronic hepatitis B infection.  Curr. Opin. Infect. Dis.  1998;11;6  Link to New therapies for the treatment of chronic hepatitis B infection.
  90. Journal ArticleReview Littlejohn M, Locarnini S, Bartholomeusz A. Targets for inhibition of hepatitis C virus replication.  Antivir. Ther. (Lond.)  1998;3;Suppl 3  Link to Targets for inhibition of hepatitis C virus replication.

    91. 1997

  91. Journal ArticleReview Nicoll A, Locarnini S. Review: Present and future directions in the treatment of chronic hepatitis B infection.  J. Gastroenterol. Hepatol.  1997;12;12  Link to Review: Present and future directions in the treatment of chronic hepatitis B infection.
  92. Journal Article Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro.  Hepatology  1997;26;1  Link to Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro.
  93. Case ReportsJournal Article Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, Angus P, Locarnini S. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation.  J. Hepatol.  1997;26;5  Link to Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation.

    94. 1996

  94. Case ReportsJournal Article McCaughan G, Angus P, Bowden S, Shaw T, Breschkin A, Sheil R, Locarnini S. Retransplantation for precore mutant-related chronic hepatitis B infection: prolonged survival in a patient receiving sequential ganciclovir/famciclovir therapy.  Liver Transpl Surg  1996;2;6  Link to Retransplantation for precore mutant-related chronic hepatitis B infection: prolonged survival in a patient receiving sequential ganciclovir/famciclovir therapy.
  95. Journal Article Luscombe C, Pedersen J, Uren E, Locarnini S. Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: effect on intrahepatic-viral DNA, RNA, and protein expression.  Hepatology  1996;24;4  Link to Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: effect on intrahepatic-viral DNA, RNA, and protein expression.
  96. Case ReportsJournal ArticleReview Fuller A, Moaven L, Spelman D, Spicer WJ, Wraight H, Curtis D, Leydon J, Doultree J, Locarnini S. Parvovirus B19 in HIV infection: a treatable cause of anemia.  Pathology  1996;28;3  Link to Parvovirus B19 in HIV infection: a treatable cause of anemia.

    97. 1995

  97. Journal ArticleResearch Support, U.S. Gov't, P.H.S. Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S, Locarnini S. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes.  J. Virol.  1995;69;6  Link to The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes.
  98. Journal Article Dean J, Bowden S, Locarnini S. Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir.  Antiviral Res.  1995;27;1-2  Link to Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir.

    99. 1994

  99. Journal Article Bartholomeusz A, Tomlinson E, Wright PJ, Birch C, Locarnini S, Weigold H, Marcuccio S, Holan G. Use of a flavivirus RNA-dependent RNA polymerase assay to investigate the antiviral activity of selected compounds.  Antiviral Res.  1994;24;4  Link to Use of a flavivirus RNA-dependent RNA polymerase assay to investigate the antiviral activity of selected compounds.
  100. Journal Article Luscombe C, Pedersen J, Bowden S, Locarnini S. Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy.  Liver  1994;14;4  Link to Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy.

    101. 1993

  101. Journal Article Jardine D, Tachedjian G, Locarnini S, Birch C. Cellular topoisomerase I activity associated with HIV-1.  AIDS Res. Hum. Retroviruses  1993;9;12  Link to Cellular topoisomerase I activity associated with HIV-1.
  102. Case ReportsJournal Article Angus P, Richards M, Bowden S, Ireton J, Sinclair R, Jones R, Locarnini S. Combination antiviral therapy controls severe post-liver transplant recurrence of hepatitis B virus infection.  J. Gastroenterol. Hepatol.  1993;8;4  Link to Combination antiviral therapy controls severe post-liver transplant recurrence of hepatitis B virus infection.
  103. Journal Article Niu J, Wang Y, Dixon R, Bowden S, Qiao M, Einck L, Locarnini S. The use of ampligen alone and in combination with ganciclovir and coumermycin A1 for the treatment of ducks congenitally-infected with duck hepatitis B virus.  Antiviral Res.  1993;21;2  Link to The use of ampligen alone and in combination with ganciclovir and coumermycin A1 for the treatment of ducks congenitally-infected with duck hepatitis B virus.
Back to page of Locarnini, Stephen.

Due mainly to homonyms, errors are possible and if you detect "false positives" or "false negatives" don't be too frustrated and please contact the webmaster.